董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 10 月 24 日 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"） 于 2025 年 10 月 24 日收到深圳证券交易所（以下简称"深交所"）出具的《关于 受理舒泰神（北京）生物制药股份有限公司向特定对象发行股票申请文件的通知》 （深证上审〔2025〕200 号），深交所对公司报送的向特定对象发行股票的申请 文件进行了核对，认为申请文件齐备，决定予以受理。 公司本次向特定对象发行股票事项尚需通过深交所审核，并获得中国证券监 督管理委员会（以下简称"中国证监会"）作出的同意注册的决定后方可实施， 最终能否通过深交所审核，并获得中国证监会作出的同意注册的决定及其时间尚 存在不确定性。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大 投资者注意投资风险。 特此公告。 舒泰神（北京）生物制药股份有限公司 证券代码：300204 证券简称：舒泰神 公告编号：2025-071 舒泰神（北京）生物制药股份有限公司 关于向特定对象发行股票申请获得深圳证券交易所受理的公告 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于舒泰神（北京）生物制药股份有限公司 向特定对象发行股票的 法律意见书 康达股发字【2025】第 0088 号 二〇二五年十月 法律意见书 释 义 在本法律意见书中除非文义另有所指，下列词语具有下述含义： | 公司、发行人或舒泰神 | 指 | 舒泰神（北京）生物制药股份有限公司 | | | --- | --- | --- | --- | | 舒泰神有限 | 指 | 舒泰神（北京）生物制药有限公司 | | | 股 A | ...

舒泰神（北京）生物制药股份有限公司 一、审计意见 我们审计了舒泰神(北京)生物制药股份有限公司(以下简称"舒泰神")财务报表, 包括2024年12月31日的合并及母公司资产负债表,2024年度的合并及母公司利润表、合并 及母公司现金流量表、合并及母公司所有者权益变动表以及相关财务报表附注。 您可使用手机"扫一扫"或进入 报告编码:苏25 2024 年度财务报表审计报告 审计报告 天衡审字(2025) 00015 号 天衡审字（2025）00015 号 天衡会计师事务所（特殊普通合伙） 舒泰神(北京)生物制药股份有限公司全体股东: 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 舒泰神2024年12月31日的合并及母公司财务状况以及2024年度的合并及母公司经营成果 和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则,我们独立于舒泰神,并履行了职业道德方面的其他责任。我们相信,我们获取 的审计证据是充分、适当的,为发表审计意见 ...

国金证券股份有限公司 关于舒泰神（北京）生物制药股份有限公司 2025 年度向特定对象发行股票并在创业板上市 之 上市保荐书 （成都市青羊区东城根上街 95 号） 二〇二五年十月 上市保荐书 声 明 国金证券股份有限公司（以下简称"国金证券"、"本保荐机构"）及保荐代 表人已根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司证券发行注册管理办法》（以下 简称"《注册管理办法》"）、《证券发行上市保荐业务管理办法》（以下简称"《保 荐业务管理办法》"）等有关法律、法规和中国证券监督管理委员会（以下简称"中 国证监会"）的有关规定以及深圳证券交易所（以下简称"深交所"）的有关业务 规则，诚实守信，勤勉尽责，严格按照依法制定的业务规则和行业自律规范出具 本上市保荐书，并保证上市保荐书的真实、准确、完整。 保荐人（主承销商） 如无特别说明，本上市保荐书中所涉简称与《舒泰神（北京）生物制药股份 有限公司 2025 年度向特定对象发行股票募集说明书》一致。 3-3-1 | 声 明 | 1 | | --- | --- | | 录 目 | 2 | | 第一 ...

国金证券股份有限公司 关于舒泰神（北京）生物制药股份有限公司 2025 年度向特定对象发行股票并在创业板上市 之 发行保荐书 保荐人（主承销商） （成都市青羊区东城根上街 95 号） 二〇二五年十月 发行保荐书 声 明 国金证券股份有限公司（以下简称"国金证券""本保荐机构"）接受舒泰神 （北京）生物制药股份有限公司（以下简称"舒泰神""公司"或"发行人"）的 委托，担任其 2025 年度向特定对象发行股票（以下简称"本次发行"）的保荐机 构。 本保荐机构及保荐代表人根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司证券发行 注册管理办法》（以下简称"《注册管理办法》"）、《证券发行上市保荐业务管理办 法》（以下简称"《保荐业务管理办法》"）等有关法律、行政法规和中国证券监督 管理委员会（以下简称"中国证监会"）及深圳证券交易所的有关规定，诚实守 信，勤勉尽责，严格按照依法制订的业务规则、行业执业规范和道德准则出具本 发行保荐书，并保证所出具文件的真实性、准确性和完整性。 如无特殊说明，本发行保荐书中的简称与《舒泰神（北京）生物制药股份有 ...

Core Viewpoint - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. experienced a decline of 5.01% in stock price, closing at 33.75 CNY per share, with a trading volume of 8.12 billion CNY and a turnover rate of 5.19%, resulting in a total market capitalization of 16.125 billion CNY [1] Group 1: Company Overview - Shuyou Shen was established on August 16, 2002, and went public on April 15, 2011. The company is primarily engaged in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue sources for Shuyou Shen include: 59.17% from injectable mouse nerve growth factor (Sutai Sheng), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2: Fund Holdings - Jin Ying Fund has a significant holding in Shuyou Shen, with its Jin Ying Medical Health Stock A (004040) holding 512,100 shares, accounting for 5.14% of the fund's net value, making it the sixth-largest holding [2] - The estimated floating loss for the fund today is approximately 911,500 CNY [2] Group 3: Fund Manager Performance - The fund manager for Jin Ying Medical Health Stock A is Han Guangzhe, who has a tenure of 12 years and 342 days, with a total fund asset size of 1.909 billion CNY. The best fund return during his tenure is 55.35%, while the worst is -56.49% [3] - Co-manager Ouyang Juan has a tenure of 3 years and 27 days, managing assets of 456 million CNY, with a best return of 0.05% and a worst return of -30.47% during her tenure [3]

Market Overview - The Shanghai Composite Index rose by 0.22% on October 23, with 21 out of 28 sectors experiencing gains. The top-performing sectors were coal and oil & petrochemicals, with increases of 1.75% and 1.53% respectively. Conversely, the telecommunications and real estate sectors saw declines of 1.51% and 0.99% respectively [1] Capital Flow Analysis - The main capital flow showed a net outflow of 33.733 billion yuan across the two markets. Six sectors experienced net inflows, with the coal sector leading at a net inflow of 1.465 billion yuan, followed by the media sector with a net inflow of 362 million yuan [1] - A total of 25 sectors faced net outflows, with the electronics sector experiencing the largest outflow of 5.435 billion yuan, followed by the machinery equipment sector with an outflow of 4.999 billion yuan. Other sectors with significant outflows included pharmaceuticals, telecommunications, and electrical equipment [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector declined by 0.60%, with a net outflow of 4.627 billion yuan. Out of 475 stocks in this sector, 183 stocks rose, 4 stocks hit the daily limit up, and 274 stocks fell [2] - Within the sector, 121 stocks saw net inflows, with five stocks receiving over 30 million yuan in net inflows. The top stock for net inflow was Jianfa Zhixin, with an inflow of 123 million yuan, followed by Sainuo Medical and Mindray Medical with inflows of 121 million yuan and 60.069 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jianfa Zhixin: +20.00% with a turnover rate of 59.71% and a net inflow of 122.929 million yuan - Sainuo Medical: +4.74% with a turnover rate of 6.99% and a net inflow of 121.228 million yuan - Mindray Medical: +0.73% with a turnover rate of 0.41% and a net inflow of 60.069 million yuan [2] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Shutaishen: -7.52% with a net outflow of 195.891 million yuan - Zhendai Medical: +2.51% with a net outflow of 185.422 million yuan - Yatai Pharmaceutical: -5.58% with a net outflow of 164.905 million yuan [3]

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.19% on October 23, with Shuyou leading the drop [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index also rose by 0.22%, closing at 13025.45 [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - ST Suwu (code: 600200) with a closing price of 1.01, up 5.21% [1] - Lianhuan Pharmaceutical (code: 600513) closed at 21.13, up 4.14% with a trading volume of 344,100 shares and a turnover of 731 million [1] - ST Nuotai (code: 688076) closed at 38.72, up 4.09% with a trading volume of 67,000 shares and a turnover of 258 million [1] - Conversely, significant decliners included: - Buzou Shen (code: 300204) with a closing price of 35.53, down 7.52% [2] - Haichen Pharmaceutical (code: 300584) closed at 51.72, down 7.25% with a trading volume of 83,600 shares and a turnover of 434 million [2] - Xiangrikui (code: 300111) closed at 8.06, down 6.06% with a trading volume of 2,061,600 shares and a turnover of 1.675 billion [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.547 billion from major funds, while retail investors contributed a net inflow of 2.56 billion [2][3] - Key stocks with significant capital flow included: - Lianhuan Pharmaceutical had a net inflow of 65.45 million from major funds, but a net outflow of 55.76 million from retail investors [3] - Kangzhi Pharmaceutical (code: 300086) saw a net inflow of 27.84 million from major funds, with a minor net outflow from retail investors [3] - Huana Pharmaceutical (code: 688799) had a net inflow of 26.15 million from major funds, but also faced outflows from retail investors [3]

Core Insights - The article highlights the significant performance of certain funds in the third quarter, particularly the "Yongying Technology Smart Selection" fund, which achieved a remarkable 194% increase, making it the top-performing fund of the year [1][2] - The report indicates a substantial growth in fund size, with "Yongying Technology Smart Selection" increasing from 1.166 billion to 11.521 billion yuan, nearly a ninefold increase in a single quarter [2] - The article also discusses the ongoing optimism in the innovative pharmaceutical sector, with funds like "Great Wall Pharmaceutical Industry Selection" showing over 100% growth [1][4] Fund Performance - "Yongying Technology Smart Selection" fund's top holdings include leading optical module stocks such as "Yizhongtian" (Xinyi Sheng, 300502), Zhongji Xuchuang (300308), and Tianfu Communication (300394), which significantly contributed to its net value [2] - The fund's share count surged from 700 million to 3.466 billion, resulting in a profit of 4.715 billion yuan for investors in the third quarter [2] - The "Great Wall Pharmaceutical Industry Selection" fund also saw its size grow from 1.132 billion to 1.790 billion yuan, with a share increase from 678 million to 932 million [5] Sector Insights - The global cloud computing industry remains a focal point, with AI model valuations increasing and a notable 100% quarter-on-quarter growth in token numbers [3] - The innovative pharmaceutical sector continues to attract attention, with funds maintaining high stock positions despite recent market adjustments [6][8] - The article suggests that the technology and pharmaceutical sectors may still have upward potential, although careful stock selection is advised [8] Future Outlook - The article indicates that the technology sector, particularly AI and cloud computing, is expected to see increased investment, with potential for new opportunities in the industry chain [9] - The innovative pharmaceutical sector is projected to strengthen its global competitiveness, supported by upcoming industry conferences and positive data trends [8] - The article emphasizes the importance of not solely relying on past performance to predict future outcomes in the cloud computing sector, highlighting the need for caution [9]

Group 1: Fund Performance and Holdings - The performance of the "Champion Fund" Yongying Technology Smart Selection has seen a remarkable increase, with a year-to-date return of nearly 195% and a net asset value growth of 234% since its inception [2][3][9] - The fund's scale surged nearly tenfold in the third quarter, growing from 1.166 billion to 11.521 billion yuan, with the number of shares increasing from 700 million to 3.466 billion [5][9] - The fund maintains a high stock position, with over 91% in equities, focusing heavily on the cloud computing sector [2][3] Group 2: Key Holdings in Cloud Computing - The top three holdings of Yongying Technology Smart Selection include Xinyi Technology, Zhongji Xuchuang, and Tianfu Communication, each with a market value exceeding 1 billion yuan [3][2] - Significant increases in holdings were observed for Huadian Co., Taicheng Light, and Tianfu Communication, with growth rates of 502.17%, 642.80%, and 347.47% respectively [3][2] Group 3: Longcheng Pharmaceutical Industry Selection - Longcheng Pharmaceutical Industry Selection has also performed well, achieving a return of 102.02% in the first three quarters, qualifying it as a "doubling fund" [7][9] - The fund's scale increased from 1.132 billion to 1.790 billion yuan in the third quarter, marking a growth of nearly 60% [9] - The fund's top three holdings include Innovent Biologics, 3SBio, and Hotgen Biotech, with each holding a market value exceeding 100 million yuan [8][7] Group 4: Investment Focus and Strategy - The investment strategy of Yongying Technology Smart Selection emphasizes the cloud computing industry, with a focus on optical communication and PCB sectors, anticipating significant technological advancements by 2027 [6][2] - Longcheng Pharmaceutical Industry Selection is shifting its focus towards clinical data, overseas licensing, and domestic sales, indicating a strategic pivot towards non-oncology sectors [9][7]